<p>Oral Maintenance Chemotherapy Using S-1/Capecitabine in Metastatic Nasopharyngeal Carcinoma Patients After Systemic Chemotherapy: A Single-Institution Experience</p>-Reference-Cited by-同舟云学术

Oral Maintenance Chemotherapy Using S-1/Capecitabine in Metastatic Nasopharyngeal Carcinoma Patients After Systemic Chemotherapy: A Single-Institution Experience

Published:2020-02 Issue: Volume:Volume 12 Page:1387-1396
ISSN:1179-1322
Container-title:Cancer Management and Research
language:en
Short-container-title:CMAR

Author:

Guo Qiaojuan,Chen Mengwei,Xu Hanchuan,Lu Tianzhu^ORCID,Zhou Han,Chen Yanyan,Zong Jingfeng,Xu Yun^ORCID,Chen Bijuan^ORCID,Wang Bingyi,Zhu Lili,Pan Jianji,Lin Shaojun^ORCID

Publisher

Informa UK Limited

Subject

Oncology

Reference58 articles.

1. Pfster DG, Spencer S, Adelstein D, et al. NCCN Clinical Practice Guidelines in Oncology. 2019.

2. Nasopharyngeal cancer: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up

3. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial

4. The combination of systemic therapy and locoregional radiotherapy prolongs survival in newly diagnosed metastatic nasopharyngeal carcinoma patients

5. Metastatic nasopharyngeal carcinoma: Patterns of care and survival for patients receiving chemotherapy with and without local radiotherapy

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Maintenance therapy improves the survival outcomes of patients with metastatic nasopharyngeal carcinoma responding to first-line chemotherapy: a multicentre, randomized controlled clinical study;Journal of Cancer Research and Clinical Oncology;2022-09-08

2. Association of Epstein–Barr virus DNA and SAA with S1 maintenance therapy outcomes in patients with metastatic nasopharyngeal carcinoma;Future Oncology;2022-07

3. Effect of Capecitabine Maintenance Therapy Plus Best Supportive Care vs Best Supportive Care Alone on Progression-Free Survival Among Patients With Newly Diagnosed Metastatic Nasopharyngeal Carcinoma Who Had Received Induction Chemotherapy;JAMA Oncology;2022-04-01

4. Maintenance metronomic chemotherapy for metastatic/recurrent nasopharyngeal carcinoma;Head & Neck;2022-04

5. Do all patients with locoregionally advanced nasopharyngeal carcinoma benefit from the maintenance chemotherapy using S-1/capecitabine?;Oral Oncology;2021-11